The ability of hIL-6Rα to enhance IL-6 mediated inhibition of M1 cell proliferation was assessed. M1 Cells were treated with increasing concentrations of hIL-6Rα in the presence of 20 ng/ml Human Interleukin-6 (hIL-6) #8904. After 72 hours, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
The purity of recombinant hIL-6Rα was determined by SDS-PAGE of 6 µg reduced (+) and nonreduced (-) recombinant IL-6Rα and staining overnight with Coomassie Blue.
With carrier: Lyophilized from a 0.22 μm filtered solution of hIL-6Rα in 20 mM Tris, pH 7.2 containing 20 μg BSA per 1 μg
hIL-6Ra. Carrier free: Lyophilized from a 0.22 μm filtered solution of hIL-6Rα in 20 mM Tris, pH 7.2.
Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles. Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
>90% as determined by SDS-PAGE of 6 μg reduced (+) and nonreduced (-) recombinant hIL-6Rα. All lots are greater than 90% pure.
Molecular Characterization: Recombinant hIL-6Rα has a calculated MW of 37,871. DTT-reduced and non-reduced protein migrate as 66 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino-terminal LAPRR of recombinant hIL-6Rα was verified by amino acid sequencing.
Recombinant Human Interleukin-6 Receptor α (hIL-6Rα) Leu20 - Asp358 (Accession #NP_000556) was expressed in human 293 cells at Cell Signaling Technology.
The IL-6 receptor is a heterodimeric complex that consists of a ligand-binding IL-6 receptor α (IL-6Rα) subunit and a signaling component, gp130 (1). Binding of IL-6 to IL-6Rα results in dimerization of receptor with gp130 and subsequent STAT3 activation (1). IL-6Rα is cleaved from the cell surface by ADAM17 (1,2). In humans, soluble IL-6Rα is also generated via alternatively spliced mRNA (1,3). Soluble IL-6Rα binds to IL-6 and can stimulate signaling via membrane bound gp130 in a process known as “trans-signaling” (1). It is through trans-signaling that IL-6 stimulates cells that do not express membrane bound IL-6Rα (1).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.